{"denoms":[{"counts":[{"groupId":"BG000","value":"9"}],"units":"Participants"}],"groups":[{"description":"Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"49","upperLimit":"72","value":"67"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Customized","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Male"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Female"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex/Gender, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2","upperLimit":"9","value":"5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Prior therapy regimes","unitOfMeasure":"number of regimens"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"88.9"}]}]}],"paramType":"NUMBER","title":"Prior autologous transplant","unitOfMeasure":"percentage of participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"3","value":"2.5"}]}]}],"description":"Revised ISS is the Revised International Staging System, which is used to stage multiple myeloma at diagnosis. It takes into account a patient's albumin, beta-2-microglobulin, lactate dehydrogenase levels, and chromosomal abnormalities detected by FISH to predict survival. There are three stages: I, II, and III. The lower the stage, the longer the progression-free survival.","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Revised ISS Stage","unitOfMeasure":"ISS Stage"}]}